Diagnostic indexes and pharmacological treatment of Alzheimer’s disease
DOI:
https://doi.org/10.61173/g4h1wh79Keywords:
Alzheimer’s disease, tau, cerebrospinal fluid, Aβ, β-site amyloid precursor protein, BACE1Abstract
The most sensible and scientific way to control Alzheimer’s disease (AD) is to diagnose and treat it early and change lifestyle and diet, so diagnostic modalities rely primarily on imaging analysis of biomarkers and examination and evaluation of serum and cerebrospinal fluid to determine AD type and disease progression in patients by several characteristic biomarkers (e.g., protein dysfunction, oxidative stress, metal ion vascular disease, mitochondrial population changes). However, there are preferences for different biomarkers in the aspect of inspection cost and patient type. As one of the signature pathologies of AD, β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) plays a crucial role in diagnosis and treatment. The difficult transmission of neurotransmitters in the synaptic gap caused by Aβ deposition is the breakthrough point for treatment and detection, which also means that detecting Aβ’s specific PET ligand in cerebrospinal fluid is more meaningful. For treatments, APP-making BACE1 becomes the key point in the AD clinical treatment. The review summarizes the diagnosis and treatment of AD based on BACE1’s mechanism and the process that causes AD.
References
[1] Breijyeh, Z. and R. Karaman. (2020) Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules., 25.
[2] Vassar, R.( 2014) BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimers Res Ther.,6(9): p. 89. Dean&Francis
[3] Perry, D., Sperling, R., Katz, R., Berry, D., Dilts, D., Hanna, D., Salloway, S., Trojanowski, J.Q., Bountra, C., Krams, M., Luthman, J., Potkin, S., Gribkoff, V., Temple, R., Wang, Y., Carrillo, M.C., Stephenson, D., Snyder, H., Liu, E., Ware, T., McKew, J., Fields, F.O., Bain, L.J., Bens, C.(2015), Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Rev Neurother 15, 327-333.
[4] Lista, S., Garaci, F.G., Ewers, M., Teipel, S., Zetterberg, H., Blennow, K., Hampel, H.(2014) CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement 10, 381- 392.
[5] Jack, C.R., Jr., Bennett, D.A., Blennow, K., Carrillo, M.C., Feldman, H.H., Frisoni, G.B., Hampel, H., Jagust, W.J., Johnson, K.A., Knopman, D.S., Petersen, R.C., Scheltens, P., Sperling, R.A., Dubois, B. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539- 547.
[6] Weller, J., Budson, A.(2018), Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res 7.
[7] Graff-Radford, J., Yong, K.X.X., Apostolova, L.G., Bouwman, F.H., Carrillo, M., Dickerson, B.C., Rabinovici, G.D., Schott, J.M., Jones, D.T., Murray, M.E.,(2021) New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol 20, 222-234.
[8] Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B.P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., Pilotto, A., Greco, A., Logroscino, G.,(2016) Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy. Immunotherapy 8, 1119-1134.
[9] Birks, J.(2006), Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006, Cd005593.
[10] Guo, J., Wang, Z., Liu, R., Huang, Y., Zhang, N., Zhang, R.(2020), Memantine, Donepezil, or Combination Therapy- What is the best therapy for Alzheimer’s Disease? A Network Meta-Analysis. Brain Behav 10, e01831.
[11] Chen, J.X., Yan, S.S.(2010) Role of mitochondrial amyloidbeta in Alzheimer’s disease. J Alzheimers Dis 20 Suppl 2, S569- 578.
[12] Cervellati, C., Valacchi, G., Zuliani, G.(2021) BACE1: from biomarker to Alzheimer’s disease therapeutical target. Aging (Albany NY) 13, 12299-12300.
[13] Bazzari, F.H., Bazzari, A.H.,(2022) BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future? Molecules 27.
[14] Hani Hojjati, S., Butler, T.A., Chiang, G.C., Habeck, C., RoyChoudhury, A., Feiz, F., Shteingart, J., Nayak, S., Ozoria, S., Fernández, A., Stern, Y., Luchsinger, J.A., Devanand, D.P., Razlighi, Q.R.,(2023) Distinct and joint effects of low and high levels of Aβ and tau deposition on cortical thickness. Neuroimage Clin 38, 103409.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
